<unk>  (PCCI) (also known in the scientific community as "CRCIs or<unk> -Related<unk><unk> s" and in lay terms as<unk> -induced<unk>  dysfunction or<unk> , chemo brain, or chemo fog) describes the<unk><unk>  that can result from<unk>  treatment. Approximately 20 to 30% of people who undergo<unk>  experience some level of<unk> . The phenomenon first came to light because of the large number of breast cancer survivors who complained of changes in memory, fluency, and other<unk>  abilities that impeded their ability to function as they had pre-chemotherapy. Although the causes and existence of<unk>  have been a subject of debate, recent studies have confirmed that<unk>  is a real, measurable side effect of<unk>  that appears in some patients. While any cancer patient may experience temporary<unk><unk>  while undergoing<unk> , patients with PCCI continue to experience these symptoms long after<unk>  has been completed. PCCI is often seen in patients treated for breast cancer, ovarian cancer, prostate cancer, and other reproductive cancers, as well as other types of cancers requiring aggressive treatment with<unk> . The clinical relevance of PCCI is significant, considering the increasing number of long-term cancer survivors in the population, many of whom may have been treated with aggressive dosing of<unk> utic agents, or with<unk>  as an adjuvant to other forms of treatment. In some patients, fear of PCCI can impact treatment decisions. The magnitude of<unk> -related<unk>  changes and their impact on the activities of daily living are uncertain.
Post-chemotherapy cognitive impairment
Paraneoplastic syndrome
Postmenopausal confusion
Postoperative cognitive dysfunction
AIDS fatigue
Sleeping disorders following traumatic brain injury
Autoimmune disease in women
Chemotherapy-induced peripheral neuropathy